Overview

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Status:
Not yet recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-[18F]MH.MZ in both populations.

Phase:

Phase 4

Details

Lead Sponsor:

Vanderbilt University Medical Center

Collaborator:

ACADIA Pharmaceuticals Inc.

Treatments:

Pimavanserin